QLT Inc. Announces Oral Retinoid Program Clinical And Regulatory Update, And Review Of Strategic Alternatives

Published: Nov 21, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VANCOUVER, British Columbia, Nov. 20, 2013 (GLOBE NEWSWIRE) -- QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today announced a clinical and regulatory update related to its synthetic oral retinoid program, as well as the initiation of a review of strategic alternatives. For the review, the Board of Directors has engaged Credit Suisse to act as financial advisor.

Help employers find you! Check out all the jobs and post your resume.

Back to news